Loading...
•
Dec 31, 2025
Glaukos Q4 2025 Earnings Report
Glaukos reported record net sales for the fourth quarter and full year 2025, driven by strong growth in glaucoma sales.
Key Takeaways
Glaukos Corporation announced record net sales of $143.1 million in Q4 2025, a 36% increase year-over-year, and $507.4 million for the full year 2025, up 32%. The company also reaffirmed its 2026 net sales guidance of $600 million to $620 million.
Record net sales of $143.1 million in Q4 2025, up 36% year-over-year on a reported basis and 34% on a constant currency basis.
Glaucoma record net sales of $119.2 million in Q4 2025, an increase of 42% year-over-year.
U.S. Glaucoma record net sales of $86.4 million in Q4 2025, up 53% year-over-year.
Full year 2025 net sales reached $507.4 million, a 32% increase year-over-year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Glaukos expects 2026 net sales to be in the range of $600 million to $620 million, driven by strong growth momentum and new product introductions.
Positive Outlook
- Reaffirmed 2026 net sales guidance of $600 million to $620 million.
- Strong growth momentum expected to continue in 2026 and beyond.
- Anticipated growth drivers include iDose TR and Epioxa.
- Continued advancement of a robust pipeline of novel, dropless platform technologies.
- Focus on meaningfully advancing the standard of care and improving patient outcomes for chronic eye diseases.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- Potential impact of general macroeconomic conditions, including foreign currency fluctuations.
- Dependence on a limited number of third-party suppliers for product components.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...